Anebulo Pharmaceuticals, Inc. (ANEB) Stock Price & Analysis
Anebulo Pharmaceuticals, Inc. (ANEB) fell 1.42% to USD 0.36 as of June 10, 2026 at 03:46 UTC, according to Nexqual real-time market data.
ANEB last closed at USD 0.36; the session ranged USD 0.35–0.36 on volume of 1,978 shares. Market capitalization is $14.48M, with a 52-week range of USD 0.3–3.42 (PNK). Source: Nexqual, June 10, 2026 at 03:46 UTC.
Key Statistics (as of June 10, 2026 at 03:46 UTC)
| Price | USD 0.36 |
|---|---|
| Change | ▼ 1.42% (down) |
| Previous Close | USD 0.36 |
| Open | USD 0.35 |
| Day Range | USD 0.35 – 0.36 |
| 52-Week Range | USD 0.3 – 3.42 |
| Volume | 1,978 shares |
| Market Cap | $14.48M |
| Exchange | PNK |
Technical Analysis (ANEB)
Nexqual's technical model rates ANEB "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.19 (neutral) |
| vs SMA50 | Below (USD 0.51) |
| MACD | -0.04 (negative) |
Analyst Ratings (ANEB)
Wall Street analysts rate ANEB "None", per Nexqual as of June 10, 2026 at 03:46 UTC.
| Consensus Rating | None |
|---|
Earnings (ANEB)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.05 vs est -0.12 ▲ beat |
| 2025-06-30 | USD -0.05 vs est -0.05 ▲ beat |
| 2025-03-31 | USD -0.04 vs est -0.05 ▲ beat |
| 2024-12-31 | USD -0.09 vs est -0.08 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Financials & Fundamentals (ANEB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -69.69% |
| Current Ratio | 6.24 |
| Total Cash | $9.04M |
| Total Debt | $0 |
| Free Cash Flow | $-3.77M |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Financial Health Score (ANEB)
Nexqual rates Anebulo Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $9M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Critical — ROE -70%, ROA -45.0% |
Ownership (ANEB)
| Insider Ownership | +40.84% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 40.78M |
| Float | 24.13M |
| Short % of Float | +2.20% |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Leadership (ANEB)
Anebulo Pharmaceuticals, Inc. is led by Richard Anthony Cunningham (age 54), CEO & Director, per Nexqual as of June 10, 2026 at 03:46 UTC.
| CEO & Director | Richard Anthony Cunningham (age 54) |
|---|---|
| Founder & Chairman | Joseph F. Lawler (age 53) |
| Acting CFO & Secretary | Daniel V. George (age 55) |
| Chief Scientific Officer | Kenneth C. Cundy (age 66) |
Major Backers & Investors (ANEB)
Notable institutional backers of Anebulo Pharmaceuticals, Inc. include Morgan Stanley, according to Nexqual as of June 10, 2026 at 03:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 0.98% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.93% |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
From Anebulo Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-09-29)
Key Strengths & Strategy (as disclosed to the SEC)
- Pediatric patients exposed to cannabis are at risk of serious and life-threatening outcomes including Central Nervous System ("CNS") depression, respiratory depression, seizures, and coma.
- The REMS typically includes risk minimization tools, medication guides, assessment plans, physician communication plans, and elements to ensure safe use, including restricted distribution methods, and patient registries.   The FDA reviews all NDAs submitted to ensure they are sufficiently complete for substantive review before it accepts them for filing.
- In addition, the FDA may require post-approval studies, including Phase 4 clinical studies, to further evaluate safety and effectiveness.
- FDA review and approval is generally required for post-approval changes to the manufacturing process and other changes to the approved product, including the addition of new indications and additional labeling claims.   Manufacturers and others involved in the manufacturing and distribution of approved products must register their establishments with the FDA and certain state agencies.
Partnerships
- Potential current competitors include Aelis Farma, which is developing a medication based on a pregnenolone derivative to treat cannabis use disorders in collaboration with Indivior PLC.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACXP | Acurx Pharmaceuticals, Inc. | USD 1.61 | ▼ 4.17% |
| JBIO | Jade Biosciences, Inc. | USD 15.22 | ▼ 10.15% |
| ADAG | Adagene Inc. | USD 3.4 | ▲ 2.41% |
| SABS | SAB Biotherapeutics, Inc. | USD 3.36 | ▼ 0.59% |
| XLO | Xilio Therapeutics, Inc. | USD 7.9 | ▲ 2.6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:46 UTC. This page is informational and not investment advice.